Autolus pricing for Nasdaq IPO reveals gains for Syncona, Woodford Patient Capital, Arix

Autolus Therapeutics has confirmed the pricing for its initial public offer on the Nasdaq index of the New York Stock Exchange, providing a monetary boost for shareholders including Syncona, the Wo...

More From BioPortfolio on "Autolus pricing for Nasdaq IPO reveals gains for Syncona, Woodford Patient Capital, Arix"